vs
MESA LABORATORIES INC（MLAB）与OCTAVE SPECIALTY GROUP INC（OSG）财务数据对比。点击上方公司名可切换其他公司
OCTAVE SPECIALTY GROUP INC的季度营收约是MESA LABORATORIES INC的1.6倍（$104.2M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -6.6%，领先12.2%），OCTAVE SPECIALTY GROUP INC同比增速更快（66.0% vs 3.6%），过去两年OCTAVE SPECIALTY GROUP INC的营收复合增速更高（42.9% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
奥克塔夫专业集团是一家专业保险控股企业，主营定制化财产与意外伤害保险产品，核心业务聚焦超额剩余保险领域，为北美地区的商业及个人客户提供定制化风险保障解决方案。
MLAB vs OSG — 直观对比
营收规模更大
OSG
是对方的1.6倍
$65.1M
营收增速更快
OSG
高出62.4%
3.6%
净利率更高
MLAB
高出12.2%
-6.6%
两年增速更快
OSG
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $104.2M |
| 净利润 | $3.6M | $-6.9M |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | — |
| 净利率 | 5.6% | -6.6% |
| 营收同比 | 3.6% | 66.0% |
| 净利润同比 | 316.6% | — |
| 每股收益（稀释后） | $0.65 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABOSG
| Q1 26 | — | $104.2M | ||
| Q4 25 | $65.1M | $66.9M | ||
| Q3 25 | $60.7M | $66.6M | ||
| Q2 25 | $59.5M | $55.0M | ||
| Q1 25 | $62.1M | $62.8M | ||
| Q4 24 | $62.8M | $65.2M | ||
| Q3 24 | $57.8M | $70.0M | ||
| Q2 24 | $58.2M | $51.0M |
净利润MLABOSG
| Q1 26 | — | $-6.9M | ||
| Q4 25 | $3.6M | $-29.7M | ||
| Q3 25 | $2.5M | $-112.6M | ||
| Q2 25 | $4.7M | $-72.7M | ||
| Q1 25 | $-7.1M | $-44.7M | ||
| Q4 24 | $-1.7M | $-20.9M | ||
| Q3 24 | $3.4M | $-27.5M | ||
| Q2 24 | $3.4M | $-750.0K |
毛利率MLABOSG
| Q1 26 | — | — | ||
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — |
营业利润率MLABOSG
| Q1 26 | — | — | ||
| Q4 25 | 12.2% | -76.7% | ||
| Q3 25 | 7.8% | -48.2% | ||
| Q2 25 | 5.1% | -41.8% | ||
| Q1 25 | 2.4% | -24.1% | ||
| Q4 24 | 9.2% | -55.5% | ||
| Q3 24 | 6.1% | -29.7% | ||
| Q2 24 | 9.6% | -28.9% |
净利率MLABOSG
| Q1 26 | — | -6.6% | ||
| Q4 25 | 5.6% | -73.8% | ||
| Q3 25 | 4.1% | -169.1% | ||
| Q2 25 | 8.0% | -132.3% | ||
| Q1 25 | -11.4% | -71.3% | ||
| Q4 24 | -2.7% | -55.1% | ||
| Q3 24 | 5.9% | -39.3% | ||
| Q2 24 | 5.8% | -1.5% |
每股收益（稀释后）MLABOSG
| Q1 26 | — | $-0.13 | ||
| Q4 25 | $0.65 | $-0.82 | ||
| Q3 25 | $0.45 | $-2.35 | ||
| Q2 25 | $0.85 | $-1.54 | ||
| Q1 25 | $-1.30 | $-1.22 | ||
| Q4 24 | $-0.31 | $-11.75 | ||
| Q3 24 | $0.63 | $-0.63 | ||
| Q2 24 | $0.62 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | — |
| 总债务越低越好 | $68.4M | $117.1M |
| 股东权益账面价值 | $186.7M | $833.6M |
| 总资产 | $434.8M | $2.3B |
| 负债/权益比越低杠杆越低 | 0.37× | 0.14× |
8季度趋势，按日历期对齐
现金及短期投资MLABOSG
| Q1 26 | — | — | ||
| Q4 25 | $29.0M | $146.4M | ||
| Q3 25 | $20.4M | $27.5M | ||
| Q2 25 | $21.3M | $22.5M | ||
| Q1 25 | $27.3M | $34.1M | ||
| Q4 24 | $27.3M | $157.2M | ||
| Q3 24 | $24.3M | $40.8M | ||
| Q2 24 | $28.5M | $14.6M |
总债务MLABOSG
| Q1 26 | — | $117.1M | ||
| Q4 25 | $68.4M | $117.6M | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | $0 | ||
| Q3 24 | $73.1M | $518.0M | ||
| Q2 24 | $74.1M | $515.0M |
股东权益MLABOSG
| Q1 26 | — | $833.6M | ||
| Q4 25 | $186.7M | $715.8M | ||
| Q3 25 | $178.5M | $843.4M | ||
| Q2 25 | $172.5M | $859.8M | ||
| Q1 25 | $159.8M | $852.2M | ||
| Q4 24 | $155.2M | $798.4M | ||
| Q3 24 | $161.5M | $1.5B | ||
| Q2 24 | $150.7M | $1.4B |
总资产MLABOSG
| Q1 26 | — | $2.3B | ||
| Q4 25 | $434.8M | $2.2B | ||
| Q3 25 | $430.4M | $2.1B | ||
| Q2 25 | $435.7M | $8.5B | ||
| Q1 25 | $433.3M | $8.3B | ||
| Q4 24 | $433.3M | $8.1B | ||
| Q3 24 | $454.1M | $9.3B | ||
| Q2 24 | $440.4M | $8.2B |
负债/权益比MLABOSG
| Q1 26 | — | 0.14× | ||
| Q4 25 | 0.37× | 0.16× | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | 0.00× | ||
| Q3 24 | 0.45× | 0.35× | ||
| Q2 24 | 0.49× | 0.38× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | — |
| 自由现金流经营现金流 - 资本支出 | $18.0M | — |
| 自由现金流率自由现金流/营收 | 27.7% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | — |
8季度趋势，按日历期对齐
经营现金流MLABOSG
| Q1 26 | — | — | ||
| Q4 25 | $18.8M | $-52.3M | ||
| Q3 25 | $8.2M | $-41.2M | ||
| Q2 25 | $1.9M | $2.1M | ||
| Q1 25 | $12.7M | $-12.6M | ||
| Q4 24 | $18.1M | $762.0K | ||
| Q3 24 | $5.3M | $48.9M | ||
| Q2 24 | $10.7M | $20.4M |
自由现金流MLABOSG
| Q1 26 | — | — | ||
| Q4 25 | $18.0M | — | ||
| Q3 25 | $7.1M | — | ||
| Q2 25 | $884.0K | — | ||
| Q1 25 | $11.9M | — | ||
| Q4 24 | $17.3M | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | $9.9M | — |
自由现金流率MLABOSG
| Q1 26 | — | — | ||
| Q4 25 | 27.7% | — | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 19.2% | — | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 6.0% | — | ||
| Q2 24 | 16.9% | — |
资本支出强度MLABOSG
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 1.5% | — |
现金转化率MLABOSG
| Q1 26 | — | — | ||
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
OSG
| Commissions | $68.2M | 65% |
| Other | $20.6M | 20% |
| Servicing and other fees | $9.4M | 9% |
| Program fees | $3.6M | 3% |
| Investment income | $2.4M | 2% |
